SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May 21, 2001
-------------
Generex Biotechnology Corporation
--------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-25169 82-049021
---------------------------- ------------ -------------------
(State or other jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
33 Harbor Square, Suite 202, Toronto, Ontario Canada M5J 2G2
--------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code 416/364-2551
------------
-----------------------------------------------------------------------------
(Former name or former address, if changed since last report)
Item 5. Other Items.
I. New Director
Effective May 21, 2001, the registrant increased the size of its Board of
Directors from six to seven members effective May 21, 2001 and elected Ivan
Lieberburg, Ph.D., M.D. as a director of the registrant to fill the vacancy thus
created. Dr. Lieberburg is an Executive Vice President and the Chief Scientific
and Medical Officer for Elan Corporation, plc ("Elan"), a worldwide
pharmaceutical and biotechnology company focused on the development and
commercialization of drugs and drug delivery technologies. The increase in the
size of the Board of the registrant and the nomination of Dr. Lieberburg to the
Board were effected as contemplated by the terms of the Securities Purchase
Agreement dated January 16, 2001 between the registrant, Elan International
Services, Ltd. and Elan. (See Exhibit 4.1 under Item 7).
Prior to joining Elan in 1987, Dr. Lieberburg held faculty positions at Albert
Einstein College of Medicine and Mt. Sinai School of Medicine in New York. Dr.
Lieberburg has been an active biomedical researcher for over 25 years, having
authored over 100 research publications and has been named to a number of honors
including Rockefeller University Fellow, Public Health Corps Scholar, National
Research Service Award, Hartford Foundation Scholar and McKnight Fellow. He
received an A.B. in biology from Cornell University, a Ph.D. from the
Rockefeller Uniersity and an M.D. from the University of Miami. He completed
post-doctoral training at the Rockefeller University and the University of
California, San Francisco ("UCSF"). He completed his clinical traning at UCSF,
where he presently holds an appointment as Clinical Professor of Medicine. He is
board certified by the Americal College of Physicians in Internal Medicine and
in Endocrinology and Metabolism.
II. Nasdaq Biotechnology Index
Effective May 21, 2001, Nasdaq removed several companies, including the
registrant, from the issues listed in the Nasdaq Biotechnology Index (the
"Index"). The changes occurred as part of Nasdaq's latest semi-annual review of
the components of the Index. Among the criteria for inclusion in the Index are
the following: the company must have a market capitalization of at least $200
million, the company's security must have a price of at least $10 and the
company's security must have an average daily trading volume of at least 100,000
shares per day.
Item 7. Exhibits
4.1 Securities Purchase Agreement dated January 16, 2001, between
Generex Biotechnology Corporation, Elan International
Services, Ltd. and Elan Corporation, plc, filed as Exhibit 4.1
to Report on Form 8-K/A filed by registrant with Commission on
February 1, 2001 and incorporated by reference herein.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GENEREX BIOTECHNOLOGY CORPORATION
Dated: May 21, 2001 By:/s/ E. Mark Perri
----------------- --------------------------------
E. Mark Perri, Chairman and CFO